ClinicalTrials.gg
RecruitingNCT07520292Updated Apr 9, 2026

Study of NTX-2001 on Alcohol Consumption in Alcohol Use Disorder

A Phase 1 interventional study of NTX-2001 and Placebo in Alcohol Use Disorder, sponsored by Newleos Therapeutics, Inc.. Recruiting at 1 site in United States. Open to participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Newleos Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,073 studies in Alcoholism with a site in United States — 187 open to participants now, 227 under way, 15 of them phase 3. Alcoholism · United States.

Planned enrollment
613th of 989
50 · median 80
Started
2026
with 54 others
Phase 1
102 of 1,073
22 open now
Primary completion
2027-03
later than 87 of 226 live
Registered
1,048th of 1,073
by date

Among the 1,073 studies in Alcoholism with a site in United States, this one is the 613th largest by planned enrollment of the 989 interventional ones that give a count, is one of 55 that started in 2026, is one of 102 in phase 1, reaches primary completion later than 87 of the 226 other live ones, and was the 1,048th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

187 of the 1,073 studies in Alcoholism with a site in United States are open now. Recruiting first, the newest first:

182 more — sign in →

All 187 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,073 studies in Alcoholism with a site in United States, or all of them as a file.
02

Study summary

The primary goal of this Phase 1b clinical trial is to evaluate the effects of a novel TAAR1 receptor partial agonist (NTX-2001) in adults with Alcohol Use Disorder (AUD). The main questions this trial aims to answer are:

  • Does NTX-2001 affect alcohol consumption in adults with AUD?
  • Is NTX-2001 safe and well tolerated in adults with AUD?

Researchers will compare the effects of NTX-2001 with matching placebo (look-alike capsule that contains no drug).

Participants will:

  • Take NTX-2001 or matching placebo every day for 2 weeks
  • Visit the clinic 4 times over the course of 10 weeks
03

Conditions studied

  • Alcohol Use Disorder

Browse trials for

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has provided written for the study and is willing to comply with all requirements of the protocol
  2. English speaker
  3. Male or female, ≥21 and ≤60 years of age.
  4. Has a (BMI) 18 to 35 kg/m2 inclusive.
  5. Meets criteria for Alcohol Use Disorder (AUD) confirmed by Mini-International Neuropsychiatric Interview (MINI).
  6. If participant is of , must commit to practicing highly effective methods of during the study and at least 14 days after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Currently seeking alcohol treatment or have been in alcohol treatment within the past 6 months
  2. Reports disliking spirits (hard liquor)
  3. Current diagnosis of substance use disorder, except for tobacco use disorder or mild cannabis use disorder as defined by the 5th Edition (DSM-5)
  4. Past or current diagnosis of schizophrenia spectrum or other psychotic disorder as defined by the DSM-5
  5. Receiving psychotropics regularly, except for a stable dose of an antidepressant for at least 2 months prior to Screening
  6. Is at risk for suicidal ideation as per C-SSRS
  7. Has moderate or severe hepatic impairment
  8. Has moderate or severe renal impairment
  9. Women who are pregnant or women who are currently breastfeeding unless they plan to stop breastfeeding for the duration of the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    NTX-2001

    Drug: NTX-2001

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugNTX-2001

    Daily (QD) x 2 weeks.

  • DrugPlacebo

    Daily (QD) x 2 weeks.

06

What researchers measure

Primary outcomes

  1. Number of drinks consumed during the alcohol drinking paradigm (ADP).

    Time frame: Day 0 to Day 14

Secondary outcomes

  1. Incidence and severity of treatment-emergent adverse events (TEAEs), vital signs, and clinical laboratory throughout the study.

    Time frame: Day 0 to Day 21

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 75 phase 1 interventional studies under Alcoholism, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2026
First posted
Apr 9, 2026
StartActual
Mar 20, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07520292
Lead sponsor
Newleos Therapeutics, Inc.
Collaborators
Yale University
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Mar 20, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Apr 9, 2026

Study contacts

Newleos Therapeutics Clinical Trial Team
Contact
clinicaltrials@newleos.com
978-780-5937

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion